NIOX
NEUTRALNIOX Group Plc Announces Director/PDMR Shareholding
The healthcare company has announced a change in shareholding by its Chief Financial Officer.
NIOX Group
70.20GBX
-1.68%
Market Cap
293.43M
Volume
1.57M
153% of avg
P/E Ratio
22.57
EPS (TTM)
3.11
Beta
-0.17
Day Range
69.00p - 71.28p
52 Week Range
53.40p70.20p77.60p
70.20p
Upcoming Events
2026
Expected benefits from revised US go-to-market strategy
High Impact Event
NIOX
NEUTRALNIOX Group Plc Announces Holding(s) in Company
The healthcare company has announced a change in major shareholding, with Raymond James Wealth Management Limited now holding 4.99% of the voting rights.
NIOX
NEUTRALNIOX Group Plc Announces Holding Change
The healthcare company has announced a change in shareholding, with Rathbones Investment Management Ltd increasing its stake in the business.
NIOX
NEUTRALNIOX Group Plc Announces Holding(s) in Company
The healthcare company has received a notification of a change in major shareholding.
NIOX
GOODNIOX Group Reports Strong H1 2025 Results with 20% Revenue Growth
The medical device company reported a 20% revenue increase and 30% adjusted EBITDA growth in H1 2025, driven by strong performance in both clinical and research segments.
NIOX
NEUTRALNIOX Group Plc Announces Holding(s) in Company
The healthcare company has announced a change in major shareholding, with Richard Griffiths and controlled holdings now holding less than 3% of the voting rights.
NIOX
NEUTRALNIOX Group Plc Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
NIOX
NEUTRALNIOX Group Plc Announces Holding(s) in Company
The healthcare company has announced a change in its major shareholding structure.
NIOX
NEUTRALNIOX Group Plc Announces PDMR/PCA Shareholding
The healthcare company has announced a transaction by a person closely associated with a senior executive.
NIOX
VERY GOODNIOX Group Delivers Strong H1 2025 Performance
The medical device company reports strong first-half performance, with revenue up 20% and Adjusted EBITDA rising 30%. The business saw robust growth in both its clinical and research divisions.